Cargando…
Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
BACKGROUND: Tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others. Although...
Autores principales: | LaHood, Allison, Rahman, Rifat, McKenna, Lindsay, Frick, Mike, Mitnick, Carole D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312388/ https://www.ncbi.nlm.nih.gov/pubmed/35877601 http://dx.doi.org/10.1371/journal.pone.0271102 |
Ejemplares similares
-
TB research requires strong protections, innovation, and increased funding in response to COVID-19
por: Nyang’wa, B. T., et al.
Publicado: (2021) -
Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022) -
Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review
por: Jhaveri, Tulip A., et al.
Publicado: (2022) -
Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017) -
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
por: Mitnick, Carole D., et al.
Publicado: (2023)